Evidence map›Paper›PMID 30925882›Full record

ArticleJournal of neuroengineering and rehabilitation2019

Muscle synergies demonstrate only minimal changes after treatment in cerebral palsy.

Benjamin R Shuman, Marije Goudriaan, Kaat Desloovere, Michael H Schwartz, Katherine M Steele

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroengineering and rehabilitation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Benjamin R ShumanDepartment of Mechanical Engineering, University of Washington, Stevens Way, Box 352600, Seattle, WA, 98195, USA.ORCID 0000-0002-6976-8021
Marije GoudriaanDepartment of Human Movement Sciences, VU university, Amsterdam, the Netherlands.
Kaat DesloovereDepartment of Rehabilitation Science, KU Leuven, Leuven, Belgium.
Michael H SchwartzJames R. Gage Center for Gait & Motion Analysis, Gillette Children's Specialty Healthcare, St. Paul, MN, USA.
Katherine M SteeleDepartment of Mechanical Engineering, University of Washington, Stevens Way, Box 352600, Seattle, WA, 98195, USA. kmsteele@uw.edu.
University of Washington · USKU Leuven · BEUniversity of Minnesota · USVrije Universiteit Amsterdam · NL

Funding

Quantifying patient-specific changes in neuromuscular control in cerebral palsyR01NS091056 · NINDS · UNIVERSITY OF WASHINGTON · PI Michael Hart Schwartz, Katherine M Steele · 2015 to 2026
$3.4M
NINDS NIH HHS R01 NS091056
6 · The paper itself

Abstract

backgroundChildren with cerebral palsy (CP) have altered synergies compared to typically-developing peers, reflecting different neuromuscular control strategies used to move. While these children receive a variety of treatments to improve gait, whether synergies change after treatment, or are associated with treatment outcomes, remains unknown.

methodsWe evaluated synergies for 147 children with CP before and after three common treatments: botulinum toxin type-A injection (n = 52), selective dorsal rhizotomy (n = 38), and multi-level orthopaedic surgery (n = 57). Changes in synergy complexity were measured by the number of synergies required to explain > 90% of the total variance in electromyography data and total variance accounted for by one synergy. Synergy weights and activations before and after treatment were compared using the cosine similarity relative to average synergies of 31 typically-developing (TD) peers.

resultsThere were minimal changes in synergies after treatment despite changes in walking patterns. Number of synergies did not change significantly for any treatment group. Total variance accounted for by one synergy increased (i.e., moved further from TD peers) after botulinum toxin type-A injection (1.3%) and selective dorsal rhizotomy (1.9%), but the change was small. Synergy weights did not change for any treatment group (average 0.001 ± 0.10), but synergy activations after selective dorsal rhizotomy did change and were less similar to TD peers (- 0.03 ± 0.07). Only changes in synergy activations were associated with changes in gait kinematics or walking speed after treatment. Children with synergy activations more similar to TD peers after treatment had greater improvements in gait.

conclusionsWhile many of these children received significant surgical procedures and prolonged rehabilitation, the minimal changes in synergies after treatment highlight the challenges in altering neuromuscular control in CP. Development of treatment strategies that directly target impaired control or are optimized to an individual's unique control may be required to improve walking function.

Indexed as

Biomechanical PhenomenaBotulinum Toxins, Type ACerebral PalsyChildElectromyographyFemaleGait Disorders, NeurologicHumansMaleMuscle, SkeletalNeuromuscular AgentsOrthopedic ProceduresRhizotomyTreatment OutcomeBotulinum Toxins, Type ANeuromuscular AgentsCP (cerebral palsy)ElectromyographyGaitMotor controlMotor disordersMuscle synergyNeurological rehabilitationSynergy plasticity

Identifiers

PMID30925882
PMCPMC6441188
OpenAlexW2942609099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.